Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sage Therapeutics, Inc. - Common Stock (NQ:SAGE)

8.680 UNCHANGED
Last Price Updated: 4:00 PM EDT, Jul 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sage Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
News headline image
SAGE Investors Have Opportunity to Lead Sage Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
Sage Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Pipeline and Business Progress
From Sage Therapeutics, Inc.
Via Business Wire
News headline image
Expert Outlook: Sage Therapeutics Through The Eyes Of 14 Analysts ↗
 
Via Benzinga
News headline image
Analyst Expectations For Sage Therapeutics's Future ↗
 
Via Benzinga
News headline image
19 Analysts Have This To Say About Sage Therapeutics ↗
 
Via Benzinga
News headline image
Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
 
Via Benzinga
News headline image
Cracking The Code: Understanding Analyst Reviews For Sage Therapeutics ↗
 
Via Benzinga
News headline image
In-Depth Examination Of 9 Analyst Recommendations For Sage Therapeutics ↗
 
Via Benzinga
News headline image
Sage, Biogen Shelve Development Of Nervous System Disorder Drug After Data Disappoints ↗
Sage Therapeutics and Biogen will end further development of SAGE-324 in ET, focusing instead on evaluating future steps. 
Via Benzinga
News headline image
Sage Therapeutics Collapses 21% After Biogen-Tied Essential Tremor Drug Fails ↗
The companies are no longer developing their drug for essential tremor treatment. 
Via Investor's Business Daily
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗
It's time to dive into the biggest pre-market stock movers for Wednesday as we check out all of the hottest news to start the day with! 
Via InvestorPlace
News headline image
Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor
From Sage Therapeutics, Inc.
Via Business Wire
News headline image
Netflix To Rally More Than 10%? Here Are 10 Top Analyst Forecasts For Friday ↗
 
Via Benzinga
News headline image
Sage Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024
From Sage Therapeutics, Inc.
Via Business Wire
News headline image
Delta Air Lines Posts Downbeat Earnings, Joins United Airlines, American Airlines And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Mama's Creations, GameStop And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Sage Therapeutics Reports Phase 2 Huntington's Data ↗
On Tuesday before the market opened, Sage Therapeutics announced findings regarding Huntington's Disease (HD) based upon topline results from the Phase 2 SURVEYOR Study. 
Via Benzinga
News headline image
Sage Therapeutics Announces Phase 2 SURVEYOR Study Reinforces Cognitive Impact of Huntington’s Disease
From Sage Therapeutics
Via Business Wire
News headline image
Sage Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
From Sage Therapeutics, Inc.
Via Business Wire
News headline image
Wall Street's Top 10 Stock Calls This Week - Sunday, June 2 ↗
What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the week of May 27 through June 2, 2024. 
Via Talk Markets
News headline image
Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month ↗
 
Via Benzinga
News headline image
Sage Therapeutics to Participate in Upcoming May Investor Conferences
From Sage Therapeutics
Via Business Wire
News headline image
SAGE Stock Earnings: Sage Therapeutics Misses EPS, Beats Revenue for Q1 2024 ↗
SAGE stock results show that Sage Therapeutics missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress
From Sage Therapeutics, Inc.
Via Business Wire
News headline image
Hilton Worldwide Reports Upbeat Results, Joins Hasbro, Vertiv Holdings And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Netflix, ON Semiconductor And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Crude Oil Dips 3%; U.S. Bancorp Profit Tops Views ↗
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling more than 100 points on Wednesday. The Dow traded up 0.04% to 37,813.77 while the NASDAQ fell 0.78% to 15,742.21.... 
Via Benzinga
Topics Stocks
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.